This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ohr Pharmaceutical Announces Additions To Ophthalmic Scientific Advisory Board

NEW YORK, Nov. 20, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCBB: OHRP) today announced the addition of two prominent ophthalmologists to its Scientific Advisory Board ("SAB") comprised of leading retinal ophthalmology experts to assist in advancing the Squalamine eye drop program through clinical efficacy trials. Jeffrey S. Heier, M.D. of Ophthalmic Consultants of Boston, and Daniel Roth, M.D., of Retina Vitreous Center in New Jersey will be joining as members of the SAB. These highly regarded experts will advise the company on its clinical programs, regulatory strategy and provide strategic guidance to support the development of Squalamine in multiple neovascular ophthalmic clinical indications, each with sizable commercial markets.

"Squalamine eye drops have the potential to significantly advance the treatment of wet-AMD, both from a patient's convenience perspective as well as its unique mechanism of action which may provide distinct or additional benefits from our current anti-VEGF agents," commented Dr. Jeffrey Heier. "I am excited to be participating in the current trial and look forward to working closely with the Ohr team on this exciting approach."

"We are delighted to be working with thought leaders in the retina community of the caliber of Drs. Heier and Roth," commented Irach B. Taraporewala, Ph.D., CEO. "The reaction of the retinal physician community to our ongoing phase II Squalamine eye drop clinical trial has been very enthusiastic. We will continue to utilize our distinguished SAB to further expand into additional neovascular ophthalmic indications."

Biography for each SAB member is below:

Dr. Jeffrey S. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina.  He serves on the Scientific Advisory Board or as Clinical Design Consultant to over twenty biotechnical or pharmaceutical companies, lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases, and has authored numerous works in peer-reviewed journals.  Dr. Heier received his medical degree from Boston University, then did his transitional internship and ophthalmology residency at Fitzsimons Army Medical Center.  Between his internship and residency, Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, for which he was awarded a Bronze Star.  Dr. Heier then completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/ Tufts University School of Medicine.  Currently, he is the Director of the Vitreoretinal Service at Ophthalmic Consultants of Boston, and Co-director of the Vitreoretinal Fellowship.   Dr. Heier is the Secretary of On-line Education and e-learning for the American Academy of Ophthalmology, Chairman of the Ophthalmic Services Committee for the New England Ophthalmological Society, Chairman of the Retina Society Credentials Committee, and an At-large Member of the American Society of Retina Specialists Executive Board.

Dr. Daniel Roth is an associate clinical professor at Robert Wood Johnson Medical School and a partner at the Retina Vitreous Center in New Jersey. He graduated summa cum laude and as valedictorian of his undergraduate class at Yeshiva University in New York City. He received his M.D. degree from Yale University, completed his residency in ophthalmology at the prestigious Bascom Palmer Eye Institute and fellowship in vitreoretinal disease and surgery at the world-famous Cleveland Clinic.  He has been honored as a member of the Alpha Omega Alpha Honors Society, Retina Society and Macula Society. He has received a Fight for Sight and a Howard Hughes Research Fellowship, as well as AAO Achievement Award and ASRS Honor award. Dr. Roth was elected by his peers for inclusion in Best Doctors in America® and in the Guide to America's Top Ophthalmologists®.  He has been a Principal Investigator for many clinical trials and sits on the committee for continuing medical education at the medical school. Dr. Roth has written chapters for numerous medical textbooks, and his research on eye disease has been published in many peer-reviewed medical journals.

About Squalamine Eye Drops

Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts not only Vascular Endothelial Growth Factor ("VEGF"), but also other angiogenic growth factors such as Platelet Derived Growth Factor ("PDGF"). Recent clinical evidence has shown PDGF to be an additional key target for the treatment of wet-AMD. The drug was previously studied using an intravenous administration in over 250 patients in Phase I and Phase II trials for the treatment of wet-AMD, with squalamine demonstrating favorable biological effect and maintained and improved visual acuity outcomes, with both early and advanced lesions responding. Ohr Pharmaceutical has developed a novel eye drop of Squalamine for the treatment of wet-AMD designed for self-administration which may provide several potential advantages over the FDA approved current standards of care, Roche/Genentech's Lucentis® and Regeneron's Eylea®, which require intravitreal injections directly into the eye. Preclinical testing has demonstrated that the eye drop formulation is both safe to ocular tissues and achieves in excess of target anti-angiogenic concentrations in the tissues of the back of the eye. In May 2012, the Squalamine Eye Drop program was granted Fast Track Designation by the U.S. FDA. A Phase II randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD was initiated in September 2012.



1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs